Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL528518 | 0.81 | — | — | |
| SCHEMBL554571 | 0.68 | — | — | |
| SCHEMBL191345 | 0.66 | ALDH1A1 (0.30) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10628287 | 0.65 | TGM2 (0.41) | MEN1KMT2ATDP1ALDH1A1LMNA | |
| SCHEMBL547912 | 0.64 | MEN1 (0.39) | PADI4MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL9959990 | 0.64 | — | — | |
| SCHEMBL2914843 | 0.64 | TGM2 (0.30) | — | |
| SCHEMBL9376833 | 0.62 | — | — | |
| SCHEMBL6278365 | 0.60 | MAPT (0.35) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL4515373 | 0.60 | ALDH1A1 (0.32) | MEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022094174-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ESOPHAGEAL CONDITIONS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| US-20220275331-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2022-09-01 | — | — | US | disclosed |
| US-20210220481-A1 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | UNIVERSITÉ PARIS CITÉ (FR) | 2021-07-22 | — | — | US | disclosed |
| EP-2598138-B1 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | UNIV BOSTON (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190225683-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| US-10314810-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-06-11 | — | — | US | disclosed |
| US-10258600-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | TRUSTEES OF BOSTON UNIVERSITY (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3368659-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | Life Technologies AS (NO) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017083809-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017072251-A1 | SELECTIVE EXPANSION OF DIFFERENT SUBPOPULATIONS OF T CELLS BY THE ALTERATION OF CELL SURFACING SIGNALS AND SIGNAL RATIO | LIFE TECHNOLOGIES AS (NO) | 2017-05-04 | — | — | WO | disclosed |
| US-20160175278-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-06-23 | — | — | US | disclosed |
| US-20130281525-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2598138-A2 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | Trustees of Boston University (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015914-A2 | ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258600-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | AHR, ARNT, AIPL1 | PADI4 3488/4885MEN1 4766/4885KMT2A 1395/4885 |
| US-20130281525-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | AHR, ARNT, AIPL1 | PADI4 3488/4885MEN1 4766/4885KMT2A 1395/4885 |
| US-20210220481-A1 | BIOCOMPATIBLE TOLEROGENIC NANOPARTICLES | IAPP, AHR, ARNT | PADI4 3554/4885MEN1 2413/4885KMT2A 3166/4885 |
| US-20160175278-A1 | ARYL HYDROCARBON RECEPTOR (AhR) MODIFIERS AS NOVEL CANCER THERAPEUTICS | AHR, ARNT, AIPL1 | PADI4 3488/4885MEN1 4766/4885KMT2A 1395/4885 |
| US-20190225683-A1 | TARGETING OXAZOLE STRUCTURES FOR THERAPY AGAINST INFLAMMATORY DISEASES | RORC, OXA1L, CX3CR1 | PADI4 2155/4885MEN1 4877/4885KMT2A 4426/4885 |
| US-10314810-B2 | Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics | AHR, ARNT, AIPL1 | PADI4 3488/4885MEN1 4766/4885KMT2A 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.